Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Table 3

Changes in the BCVA from baseline after IVR treatment in the patients having subretinal hemorrhage before treatment.

	1 month (𝑛=60)		𝑃 value	3 months (𝑛=60)		𝑃 value
Subretinal hemorrhage	Mean	Median; (Interquartile range)		Mean	Median; (Interquartile range)
>1 DA (𝑛=14)	0.0053	0.00 (−0.079–0.18)	.57*	−0.040	0.00 (−0.097–0.020)	1.00*
≦1 DA (𝑛=46)	−0.064	−0.023 (−0.12–0.00)	.0008*	−0.11	−0.097 (−0.18–0.00)	.0002*
𝑃 value		.065^†			.10^†

BCVA: best-corrected visual acuity (LogMAR); DA: disc area.
*Wilcoxon’s signed-rank test (comparison to baseline).
^†Mann-Whitney 𝑈 test (comparison between PCV and tAMD at the same month).